The current study demonstrates that plasma biomarkers of AD pathology (pTau-181) and astrogliosis (GFAP), but not neuronal injury (NfL), may serve as markers of future brain atrophy and cognitive decline among cognitively unimpaired older adults in the community. The gene discussed is GFAP; the disease is Alzheimer disease.